UKTN
Laverock Therapeutics has been awarded two new grants totalling in excess of £2.2m to support the next generation of its gene-control platform development and expansion into additional non-oncology therapeutics areas. The biotech is developing disease-responsive advanced therapies through its programmable gene control technology. To date, Laverock’s gene-control platform has been demonstrated across therapeutic applications and […] The post Laverock Therapeutics awarded £2.2m through innovation grants appeared first on UKTN .
Go to News Site